{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:20:47Z","timestamp":1793654447440,"version":"4.5.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>GDF15 has recently emerged as a key driver of the development of various disease conditions including cancer cachexia. Not only the tumor itself but also adverse effects of chemotherapy have been reported to contribute to increased GDF15. Although regulation of GDF15 transcription by BET domain has recently been reported, the molecular mechanisms of GDF15 gene regulation by drugs are still unknown, leaving uncertainty about the safe and effective therapeutic strategies targeting GDF15. We screened various cardiotoxic drugs and BET inhibitors for their effects on GDF15 regulation in human cardiomyocytes and cancer cell lines and analyzed in-house and public gene signature databases. We found that DNA damaging drugs induce GDF15 in cardiomyocytes more strongly than drugs with other modes of action. In cancer cells, GDF15 induction varied depending on drug- and cell type-specific gene signatures including mutations in <jats:italic>PI3KCA, TP53, BRAF<\/jats:italic> and <jats:italic>MUC16<\/jats:italic>. GDF15 suppression by BET inhibition is particularly effective in cancer cells with low activity of the PI3K\/Akt axis and high extracellular concentrations of pantothenate. Our findings provide insights that the risk for GDF15 overexpression and concomitant cachexia can be reduced by a personalized selection of anticancer drugs and patients for precision medicine.<\/jats:p>","DOI":"10.1038\/s41598-023-38450-w","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T10:02:02Z","timestamp":1690365722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Molecular basis of GDF15 induction and suppression by drugs in cardiomyocytes and cancer cells toward precision medicine"],"prefix":"10.1038","volume":"13","author":[{"given":"Lisa-Maria","family":"Winter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Schatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"Tissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Wiora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Tontsch-Grunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Colbatzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Stierstorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Wook","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"38450_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/jcsm.12077","volume":"7","author":"L Lerner","year":"2016","unstructured":"Lerner, L. et al. MAP3K11\/GDF15 axis is a critical driver of cancer cachexia. J. Cachexia Sarcopenia Muscle 7, 467\u2013482 (2016).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"38450_CR2","doi-asserted-by":"publisher","first-page":"e8636","DOI":"10.15252\/msb.20188636","volume":"15","author":"K Shimada","year":"2019","unstructured":"Shimada, K. & Mitchison, T. J. Unsupervised identification of disease states from high-dimensional physiological and histopathological profiles. Mol. Syst. Biol. 15, e8636 (2019).","journal-title":"Mol. Syst. Biol."},{"key":"38450_CR3","first-page":"1","volume":"83","author":"SN Breit","year":"2020","unstructured":"Breit, S. N., Brown, D. A. & Tsai, V.W.-W. The GDF15-GFRAL pathway in health and metabolic disease: Friend or foe?. Ann. Rev. Physiol. 83, 1\u201325 (2020).","journal-title":"Ann. Rev. Physiol."},{"key":"38450_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1210\/endrev\/bnaa007","volume":"41","author":"SM Lockhart","year":"2020","unstructured":"Lockhart, S. M., Saudek, V. & O\u2019Rahilly, S. GDF15: A hormone conveying somatic distress to the brain. Endocr. Rev. 41, 610\u2013642 (2020).","journal-title":"Endocr. Rev."},{"key":"38450_CR5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3389\/fimmu.2020.00951","volume":"11","author":"J Wischhusen","year":"2020","unstructured":"Wischhusen, J., Melero, I. & Fridman, W. H. Growth\/differentiation factor-15 (GDF-15): From biomarker to novel targetable immune checkpoint. Front. Immunol. 11, 951 (2020).","journal-title":"Front. Immunol."},{"key":"38450_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41556-020-00628-z","volume":"23","author":"E Yeom","year":"2021","unstructured":"Yeom, E. et al. Tumour-derived Dilp8\/INSL3 induces cancer anorexia by regulating feeding neuropeptides via Lgr3\/8 in the brain. Nat. Cell Biol. 23, 172\u2013183 (2021).","journal-title":"Nat. Cell Biol."},{"key":"38450_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/21548331.2018.1530831","volume":"47","author":"D Jain","year":"2019","unstructured":"Jain, D. & Aronow, W. Cardiotoxicity of cancer chemotherapy in clinical practice. Hosp. Pract. 47, 6\u201315 (2019).","journal-title":"Hosp. Pract."},{"key":"38450_CR8","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.cmet.2020.10.023","volume":"32","author":"DM Breen","year":"2020","unstructured":"Breen, D. M. et al. GDF-15 neutralization alleviates platinum-based chemotherapy-induced emesis, anorexia, and weight loss in mice and nonhuman primates. Cell Metab. 32, 938-950.e6 (2020).","journal-title":"Cell Metab."},{"key":"38450_CR9","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/cam4.1330","volume":"7","author":"G Dong","year":"2018","unstructured":"Dong, G. et al. Angiogenesis enhanced by treatment damage to hepatocellular carcinoma through the release of GDF15. Cancer Med. Us. 7, 820\u2013830 (2018).","journal-title":"Cancer Med. Us."},{"key":"38450_CR10","doi-asserted-by":"publisher","first-page":"103533","DOI":"10.1016\/j.jprot.2019.103533","volume":"210","author":"W Jiang","year":"2020","unstructured":"Jiang, W. et al. Identification of urinary candidate biomarkers of cisplatin-induced nephrotoxicity in patients with carcinoma. J. Proteomics 210, 103533 (2020).","journal-title":"J. Proteomics"},{"key":"38450_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.tox.2014.12.018","volume":"328","author":"G Holmgren","year":"2015","unstructured":"Holmgren, G. et al. Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells. Toxicology 328, 102\u2013111 (2015).","journal-title":"Toxicology"},{"key":"38450_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/CD9.0000000000000051","volume":"02","author":"Z Yan","year":"2022","unstructured":"Yan, Z. et al. Cardioprotective effect of growth differentiation factor 15 against isoproterenol-induced cardiomyocyte apoptosis via regulation of the mitochondrial fusion. Cardiol. Discov. 02, 89\u201396 (2022).","journal-title":"Cardiol. Discov."},{"key":"38450_CR13","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/eurjhf\/hfs120","volume":"14","author":"SI Lok","year":"2012","unstructured":"Lok, S. I. et al. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur. J. Heart Fail. 14, 1249\u20131256 (2012).","journal-title":"Eur. J. Heart Fail."},{"key":"38450_CR14","doi-asserted-by":"publisher","first-page":"eaah5084","DOI":"10.1126\/scitranslmed.aah5084","volume":"9","author":"Q Duan","year":"2017","unstructured":"Duan, Q. et al. BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. Sci. Transl. Med. 9, eaah5084 (2017).","journal-title":"Sci. Transl. Med."},{"key":"38450_CR15","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1373\/clinchem.2015.241232","volume":"61","author":"M Putt","year":"2015","unstructured":"Putt, M. et al. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin. Chem. 61, 1164\u20131172 (2015).","journal-title":"Clin. Chem."},{"key":"38450_CR16","doi-asserted-by":"publisher","first-page":"e3001517","DOI":"10.1371\/journal.pbio.3001517","volume":"20","author":"JF Lu","year":"2022","unstructured":"Lu, J. F. et al. Camptothecin effectively treats obesity in mice through GDF15 induction. Plos Biol. 20, e3001517 (2022).","journal-title":"Plos Biol."},{"key":"38450_CR17","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.1074\/jbc.M305295200","volume":"279","author":"SJ Baek","year":"2004","unstructured":"Baek, S. J., Kim, J.-S., Nixon, J. B., DiAugustine, R. P. & Eling, T. E. Expression of NAG-1, a transforming growth factor-\u03b2 superfamily member, by troglitazone requires the early growth response gene EGR-1 *. J. Biol. Chem. 279, 6883\u20136892 (2004).","journal-title":"J. Biol. Chem."},{"key":"38450_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1073\/pnas.97.1.109","volume":"97","author":"M Tan","year":"2000","unstructured":"Tan, M., Wang, Y., Guan, K. & Sun, Y. PTGF-\u03b2, a type \u03b2 transforming growth factor (TGF-\u03b2) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-\u03b2 signaling pathway. Proc. Natl. Acad. Sci. 97, 109\u2013114 (2000).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"38450_CR19","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.celrep.2018.01.044","volume":"22","author":"JE Jones","year":"2018","unstructured":"Jones, J. E. et al. Supraphysiologic administration of GDF11 induces cachexia in part by upregulating GDF15. Cell Rep. 22, 1522\u20131530 (2018).","journal-title":"Cell Rep."},{"key":"38450_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41420-021-00462-8","volume":"7","author":"F Guo","year":"2021","unstructured":"Guo, F. et al. NR5A2 transcriptional activation by BRD4 promotes pancreatic cancer progression by upregulating GDF15. Cell Death Discov. 7, 78 (2021).","journal-title":"Cell Death Discov."},{"key":"38450_CR21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/jcsm.12909","volume":"13","author":"H AlSudais","year":"2022","unstructured":"AlSudais, H., Rajgara, R., Saleh, A. & Wiper-Bergeron, N. C\/EBP\u03b2 promotes the expression of atrophy-inducing factors by tumours and is a central regulator of cancer cachexia. J. Cachexia Sarcopenia Muscle 13, 743\u2013757 (2022).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"38450_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1083\/jcb.201607110","volume":"216","author":"HK Chung","year":"2017","unstructured":"Chung, H. K. et al. Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis. J. Cell Biol. 216, 149\u2013165 (2017).","journal-title":"J. Cell Biol."},{"key":"38450_CR23","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/carcin\/bgq016","volume":"31","author":"S-H Lee","year":"2010","unstructured":"Lee, S.-H., Krisanapun, C. & Baek, S. J. NSAID-activated gene-1 as a molecular target for capsaicin-induced apoptosis through a novel molecular mechanism involving GSK3\u03b2, C\/EBP\u03b2 and ATF3. Carcinogenesis 31, 719\u2013728 (2010).","journal-title":"Carcinogenesis"},{"key":"38450_CR24","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1172\/JCI91561","volume":"127","author":"NM Ratnam","year":"2017","unstructured":"Ratnam, N. M. et al. NF-\u03baB regulates GDF-15 to suppress macrophage surveillance during early tumor development. J. Clin. Invest. 127, 3796\u20133809 (2017).","journal-title":"J. Clin. Invest."},{"key":"38450_CR25","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/nature09589","volume":"468","author":"E Nicodeme","year":"2010","unstructured":"Nicodeme, E. et al. Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119\u20131123 (2010).","journal-title":"Nature"},{"key":"38450_CR26","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1038\/s41388-018-0150-2","volume":"37","author":"D Gerlach","year":"2018","unstructured":"Gerlach, D. et al. The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML. Oncogene 37, 2687\u20132701 (2018).","journal-title":"Oncogene"},{"key":"38450_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.cell.2016.02.036","volume":"165","author":"L Baranello","year":"2016","unstructured":"Baranello, L. et al. RNA polymerase II regulates topoisomerase 1 activity to favor efficient transcription. Cell 165, 357\u2013371 (2016).","journal-title":"Cell"},{"key":"38450_CR28","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cell.2013.07.013","volume":"154","author":"P Anand","year":"2013","unstructured":"Anand, P. et al. BET bromodomains mediate transcriptional pause release in heart failure. Cell 154, 569\u2013582 (2013).","journal-title":"Cell"},{"key":"38450_CR29","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","volume":"54","author":"J Shi","year":"2014","unstructured":"Shi, J. & Vakoc, C. R. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 54, 728\u2013736 (2014).","journal-title":"Mol. Cell"},{"key":"38450_CR30","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","volume":"124","author":"T Shorstova","year":"2021","unstructured":"Shorstova, T., Foulkes, W. D. & Witcher, M. Achieving clinical success with BET inhibitors as anti-cancer agents. Brit. J. Cancer 124, 1478\u20131490 (2021).","journal-title":"Brit. J. Cancer"},{"key":"38450_CR31","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1038\/oncsis.2016.3","volume":"5","author":"PE Porporato","year":"2016","unstructured":"Porporato, P. E. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis 5, e200\u2013e200 (2016).","journal-title":"Oncogenesis"},{"key":"38450_CR32","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/jcsm.12059","volume":"6","author":"CC Ezeoke","year":"2015","unstructured":"Ezeoke, C. C. & Morley, J. E. Pathophysiology of anorexia in the cancer cachexia syndrome. J. Cachexia Sarcopenia Muscle 6, 287\u2013302 (2015).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"38450_CR33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.trecan.2022.01.004","volume":"8","author":"EE Talbert","year":"2022","unstructured":"Talbert, E. E. & Guttridge, D. C. Emerging signaling mediators in the anorexia\u2013cachexia syndrome of cancer. Trends Cancer 8, 397\u2013403 (2022).","journal-title":"Trends Cancer"},{"issue":"24","key":"38450_CR34","doi-asserted-by":"publisher","first-page":"6807","DOI":"10.1158\/0008-5472.CAN-18-0989","volume":"78","author":"A Monks","year":"2018","unstructured":"Monks, A. et al. The NCI transcriptional pharmacodynamics workbench: A tool to examine dynamic expression profiling of therapeutic response in the NCI-60 cell line panel. Cancer Res. 78(24), 6807\u20136817 (2018).","journal-title":"Cancer Res."},{"key":"38450_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-023-00936-y","volume":"58","author":"F Zeng","year":"2023","unstructured":"Zeng, F. et al. BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression. Exp. Mol. Med. 58, 1\u201313. https:\/\/doi.org\/10.1038\/s12276-023-00936-y (2023).","journal-title":"Exp. Mol. Med."},{"key":"38450_CR36","doi-asserted-by":"publisher","first-page":"e8636","DOI":"10.15252\/msb.20188636","volume":"15","author":"K Shimada","year":"2019","unstructured":"Shimada, K. & Mitchison, T. J. Unsupervised identification of disease states from high-dimensional physiological and histopathological profiles. Mol. Syst. Biol. 15, e8636 (2019).","journal-title":"Mol. Syst. Biol."},{"key":"38450_CR37","doi-asserted-by":"publisher","first-page":"9634","DOI":"10.18632\/oncotarget.7457","volume":"7","author":"H Park","year":"2016","unstructured":"Park, H., Kim, C.-H., Jeong, J.-H., Park, M. & Kim, K. S. GDF15 contributes to radiation-induced senescence through the ROS-mediated p16 pathway in human endothelial cells. Oncotarget 7, 9634\u20139644 (2016).","journal-title":"Oncotarget"},{"key":"38450_CR38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41586-021-04133-7","volume":"600","author":"L Mulderrig","year":"2021","unstructured":"Mulderrig, L. et al. Aldehyde-driven transcriptional stress triggers an anorexic DNA damage response. Nature 600, 158\u2013163 (2021).","journal-title":"Nature"},{"key":"38450_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1083\/jcb.201607110","volume":"216","author":"HK Chung","year":"2017","unstructured":"Chung, H. K. et al. Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis. J. Cell Biol. 216, 149\u2013165 (2017).","journal-title":"J. Cell Biol."},{"key":"38450_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mito.2014.10.006","volume":"20","author":"Y Fujita","year":"2015","unstructured":"Fujita, Y. et al. GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases. Mitochondrion 20, 34\u201342 (2015).","journal-title":"Mitochondrion"},{"key":"38450_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-2869-1","author":"Advances in Mitochondrial Medicine","year":"2012","unstructured":"Advances in Mitochondrial Medicine. Adv. Exp. Med. Biol. https:\/\/doi.org\/10.1007\/978-94-007-2869-1 (2012).","journal-title":"Adv. Exp. Med. Biol."},{"key":"38450_CR42","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/toxsci\/kfn157","volume":"106","author":"Y Will","year":"2008","unstructured":"Will, Y. et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol. Sci. 106, 153\u2013161 (2008).","journal-title":"Toxicol. Sci."},{"key":"38450_CR43","doi-asserted-by":"publisher","first-page":"113902","DOI":"10.1016\/j.bcp.2020.113902","volume":"176","author":"MA Rodr\u00edguez-Hern\u00e1ndez","year":"2020","unstructured":"Rodr\u00edguez-Hern\u00e1ndez, M. A. et al. Dose-dependent regulation of mitochondrial function and cell death pathway by sorafenib in liver cancer cells. Biochem. Pharmacol. 176, 113902 (2020).","journal-title":"Biochem. Pharmacol."},{"key":"38450_CR44","doi-asserted-by":"publisher","first-page":"8943","DOI":"10.1038\/s41598-022-12519-4","volume":"12","author":"F Ek","year":"2022","unstructured":"Ek, F. et al. Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma. Sci. Rep. UK 12, 8943 (2022).","journal-title":"Sci. Rep. UK"},{"key":"38450_CR45","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbcan.2013.12.002","volume":"1845","author":"F Yang","year":"2014","unstructured":"Yang, F., Teves, S. S., Kemp, C. J. & Henikoff, S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochim. Biophys. Acta BBA Rev. Cancer 1845, 84\u201389 (2014).","journal-title":"Biochim. Biophys. Acta BBA Rev. Cancer"},{"key":"38450_CR46","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.molcel.2020.04.034","volume":"78","author":"S-Y Wu","year":"2020","unstructured":"Wu, S.-Y. et al. Opposing functions of BRD4 isoforms in breast cancer. Mol. Cell 78, 1114-1132.e10 (2020).","journal-title":"Mol. Cell"},{"key":"38450_CR47","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/s41467-017-01645-7","volume":"8","author":"M Segatto","year":"2017","unstructured":"Segatto, M. et al. Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival. Nat. Commun. 8, 1707 (2017).","journal-title":"Nat. Commun."},{"key":"38450_CR48","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.ccell.2018.11.005","volume":"34","author":"AB Iniguez","year":"2018","unstructured":"Iniguez, A. B. et al. Resistance to epigenetic-targeted therapy engenders tumor cell vulnerabilities associated with enhancer remodeling. Cancer Cell 34, 922-938.e7 (2018).","journal-title":"Cancer Cell"},{"key":"38450_CR49","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/sj.leu.2403653","volume":"19","author":"VL Grandage","year":"2005","unstructured":"Grandage, V. L., Gale, R. E., Linch, D. C. & Khwaja, A. PI3-kinase\/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways. Leukemia 19, 586\u2013594 (2005).","journal-title":"Leukemia"},{"key":"38450_CR50","doi-asserted-by":"publisher","first-page":"38553","DOI":"10.1038\/srep38553","volume":"6","author":"S Medunjanin","year":"2016","unstructured":"Medunjanin, S. et al. GSK-3\u03b2 controls NF-kappaB activity via IKK\u03b3\/NEMO. Sci. Rep. UK 6, 38553 (2016).","journal-title":"Sci. Rep. UK"},{"key":"38450_CR51","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.1092734","volume":"303","author":"JE Chipuk","year":"2004","unstructured":"Chipuk, J. E. et al. Direct activation of bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303, 1010\u20131014 (2004).","journal-title":"Science"},{"key":"38450_CR52","doi-asserted-by":"publisher","first-page":"753","DOI":"10.4161\/cc.23597","volume":"12","author":"S-J Wang","year":"2013","unstructured":"Wang, S.-J. et al. p53-dependent regulation of metabolic function through transcriptional activation of pantothenate kinase-1 gene. Cell Cycle 12, 753\u2013761 (2013).","journal-title":"Cell Cycle"},{"key":"38450_CR53","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41586-022-04984-8","volume":"608","author":"CC Dibble","year":"2022","unstructured":"Dibble, C. C. et al. PI3K drives the de novo synthesis of coenzyme A from vitamin B5. Nature 608, 192\u2013198 (2022).","journal-title":"Nature"},{"key":"38450_CR54","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/CCO.0000000000000763","volume":"33","author":"TG Halder","year":"2021","unstructured":"Halder, T. G., Soldi, R. & Sharma, S. Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics. Curr. Opin. Oncol. 33, 526\u2013531 (2021).","journal-title":"Curr. Opin. Oncol."},{"key":"38450_CR55","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.bcp.2012.11.025","volume":"85","author":"X Wang","year":"2013","unstructured":"Wang, X., Baek, S. J. & Eling, T. E. The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1\/GDF15) in cancer. Biochem. Pharmacol. 85, 597\u2013606 (2013).","journal-title":"Biochem. Pharmacol."},{"key":"38450_CR56","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nm.4087","volume":"22","author":"PW Burridge","year":"2016","unstructured":"Burridge, P. W. et al. Human induced pluripotent stem cell\u2013derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat. Med. 22, 547\u2013556 (2016).","journal-title":"Nat. Med."},{"issue":"3","key":"38450_CR57","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41416-022-01815-5","volume":"127","author":"U Tontsch-Grunt","year":"2022","unstructured":"Tontsch-Grunt, U. et al. Therapeutic impact of BET inhibitor BI 894999 treatment: Backtranslation from the clinic. Brit. J. Cancer 127(3), 577\u2013586 (2022).","journal-title":"Brit. J. Cancer"},{"key":"38450_CR58","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","volume":"11","author":"MH Hofmann","year":"2021","unstructured":"Hofmann, M. H. et al. BI-3406, a potent and selective SOS1\u2013KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discov. 11, 142\u2013157 (2021).","journal-title":"Cancer Discov."},{"key":"38450_CR59","first-page":"3227","volume":"80","author":"A Wernitznig","year":"2020","unstructured":"Wernitznig, A. et al. Abstract 3227: CLIFF, a bioinformatics software tool to explore molecular differences between two sets of cancer cell lines. Clin. Res. Exclud. Clin. Trials 80, 3227 (2020).","journal-title":"Clin. Res. Exclud. Clin. Trials"},{"key":"38450_CR60","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi, M. et al. Next-generation characterization of the cancer cell line encyclopedia. Nature 569, 503\u2013508 (2019).","journal-title":"Nature"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38450-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38450-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38450-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T10:03:48Z","timestamp":1690365828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38450-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["38450"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-38450-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"13 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are employed by Boehringer Ingelheim.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12061"}}